The Swanson Reed Patent of the Month for Georgia for October 2026 has been awarded for US Patent No. 12,721,731, titled “Expandable interbody device.” The patent was granted to Centinel Spine, Inc., with inventors listed as John H. Peloza, Scott L. Kimmell, and James D. Webb. This patent describes an advanced spinal fusion implant engineered to deliver controlled structural expansion within the intervertebral disc space following insertion.
The system addresses persistent challenges in minimally invasive spine surgery by allowing a low profile during initial insertion, which reduces tissue disruption and nerve root retraction. Once in position, the implant expands to restore anatomical disc height and lordotic alignment. Swanson Reed selected this patent based on its mechanical novelty, structural integrity, and clear clinical utility within the orthopedic device sector.
Innovation and Mechanical Advantages
The design set forth in US Patent No. 12,721,731 provides several distinct technological improvements over conventional fixed and expandable interbody cages. Traditional expandable devices frequently rely on complex internal gearing mechanisms that can increase failure rates under physiological loads or reduce the internal volume available for bone graft material.
The key innovations described in this patent include:
- Optimized Expansion Geometry: The internal actuation mechanism allows multi-planar expansion, adjusting both vertical height and lordotic angle while maintaining structural stability under compression.
- Maximized Graft Area: By streamlining the internal drive components, the cage retains a large central hollow core for bone graft placement, promoting higher rates of bony fusion.
- Controlled Mechanical Advantage: The deployment mechanism minimizes the force required by the surgeon during expansion, offering tactile feedback and preventing over-distraction of adjacent vertebral endplates.
- Integrated Locking Features: The device incorporates a positive locking system that prevents post-operative collapse or reverse-threading under cyclical loading.
Georgia Patent of the Month Recognition
Swanson Reed recognized this invention as the October 2026 Patent of the Month for the state of Georgia due to its combination of intellectual property strength, engineering precision, and potential market impact. Georgia continues to grow as a regional hub for biomedical engineering and health technology, and this patent represents a noteworthy contribution to the state’s medical device ecosystem.
The patent demonstrates a clear solution to documented surgical challenges, backed by robust mechanical claims. Its balanced approach to biomechanical load-bearing and minimally invasive surgical access distinguishes it among medical device patents issued during this period.
Eligibility for US R&D Tax Credits
The development of an expandable interbody device of this nature involves significant technological risk and technical iteration, making the underlying development activities eligible for the United States Federal Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41, as well as applicable Georgia state R&D tax incentives. To qualify under the four-part test, the company must demonstrate that the project fulfilled specific statutory requirements:
First, the development served a permissible purpose by seeking to create a new medical device with improved functionality, structural integrity, and surgical efficiency. Second, the engineering team worked to eliminate technical uncertainty regarding whether a low-profile mechanism could withstand axial lumbar loads without increasing mechanical failure rates or sacrificing internal graft volume. Third, the path to resolution required a systematic process of experimentation, involving CAD modeling, Finite Element Analysis (FEA), biomechanical stress testing, rapid prototyping, and iterative functional trials. Fourth, the work was fundamentally technological in nature, drawing directly upon principles of mechanical engineering, biomechanics, metallurgy, and material science. Consequently, qualified research expenses, including internal engineering wages, prototype fabrication supplies, and third-party testing fees incurred during the development process, represent eligible costs for tax credit claims.
